# Title

 Food and Drugs. PART 350â€”ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE


# ID

 CFR-2018-title21-vol5.Pt. 350


# Structured Analysis Summary

| Type        | Values                                                                                        |
|:------------|:----------------------------------------------------------------------------------------------|
| Constraints | ['within', 'before']                                                                          |
| Duration    | ['24.0 hour']                                                                                 |
| Condition   | ['subject to', 'if', 'unless']                                                                |
| Entities    | ['U.S', 'Rockville, MD', 'Scope', 'Information', 'Food', 'Antiperspirant', 'Freedom', 'Uses'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                    |
|:--------------|:-----------------------------------------------------------------------------------------------------------|
| within        | the product consists of any of the following within  the established concentration and dosage formulation. |
| before        | (3) &#8220;Ask a doctor  before  use if you have kidney disease&#8221;.                                    |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24.0 hour  | (3) For products that demonstrate standard effectiveness (20 percent sweat reduction) over a 24-hour period, the labeling may state [select one of the following: &#8220;all day protection,&#8221; &#8220;lasts all day,&#8221; &#8220;lasts 24 hours,&#8221; or &#8220;24 hour protection&#8221;].                                                                                                                                               |
| 24.0 hour  | (3) For products that demonstrate standard effectiveness (20 percent sweat reduction) over a 24-hour period, the labeling may state [select one of the following: &#8220;all day protection,&#8221; &#8220;lasts all day,&#8221; &#8220;lasts 24 hours,&#8221; or &#8220;24 hour protection&#8221;].                                                                                                                                               |
| 24.0 hour  | (3) For products that demonstrate standard effectiveness (20 percent sweat reduction) over a 24-hour period, the labeling may state [select one of the following: &#8220;all day protection,&#8221; &#8220;lasts all day,&#8221; &#8220;lasts 24 hours,&#8221; or &#8220;24 hour protection&#8221;].                                                                                                                                               |
| 24.0 hour  | (5) Products that demonstrate extra effectiveness (30 percent sweat reduction) sustained over a 24-hour period may state the claims in paragraphs (b)(3) and (b)(4) of this section either individually or combined, e.g., &#8220;24 hour extra effective protection&#8221;, &#8220;all day extra effective protection,&#8221; &#8220;extra effective protection lasts 24 hours,&#8221; or &#8220;extra effective protection lasts all day&#8221;. |
| 24.0 hour  | (5) Products that demonstrate extra effectiveness (30 percent sweat reduction) sustained over a 24-hour period may state the claims in paragraphs (b)(3) and (b)(4) of this section either individually or combined, e.g., &#8220;24 hour extra effective protection&#8221;, &#8220;all day extra effective protection,&#8221; &#8220;extra effective protection lasts 24 hours,&#8221; or &#8220;extra effective protection lasts all day&#8221;. |
| 24.0 hour  | (5) Products that demonstrate extra effectiveness (30 percent sweat reduction) sustained over a 24-hour period may state the claims in paragraphs (b)(3) and (b)(4) of this section either individually or combined, e.g., &#8220;24 hour extra effective protection&#8221;, &#8220;all day extra effective protection,&#8221; &#8220;extra effective protection lasts 24 hours,&#8221; or &#8220;extra effective protection lasts all day&#8221;. |


## Condition

| Condition   | Context                                                                                                                |
|:------------|:-----------------------------------------------------------------------------------------------------------------------|
| if          | as safe and effective and is not misbranded if it meets each condition in this part and                                |
| unless      | Regulations are to chapter I of title 21 unless  otherwise noted.                                                      |
| if          | product contains the established name of the drug, if  any, and ident                                                  |
| subject to  | used, as provided in &#167;&#8201;330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal |
| if          | (2) &#8220;Stop use  if  rash or irritation occurs&#8221;.                                                             |
| if          | (3) &#8220;Ask a doctor before use  if  you have kidney disease&#8221;.                                                |


## Entities

| Entities       | Context                                                                                                 |
|:---------------|:--------------------------------------------------------------------------------------------------------|
| Food           | Food  and Drugs.                                                                                        |
| Scope          | Scope .                                                                                                 |
| Antiperspirant | Antiperspirant .                                                                                        |
| U.S            | zirconium to chloride atomic ratios described in the U.S . Pharmacopeia-National Formulary.             |
| Uses           | of the product states, under the heading &#8220; Uses ,&#8221; the phrase listed in paragraph (b)(1) of |
| Rockville, MD  | 1061,  Rockville, MD  20852.                                                                            |
| Information    | a nominal charge by submitting a Freedom of Information (FOI) request in writing to FDA's Division of   |
| Freedom        | request for a nominal charge by submitting a Freedom of Information (FOI) request in writing to FDA's   |
| Information    | a nominal charge by submitting a Freedom of Information (FOI) request in writing to FDA's Division of   |


